Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore by Goh, ET & Morgan, MY
1 
APT-1546-2016R1 
 
Review article: pharmacotherapy for alcohol dependence: the 
why, the what and the wherefore 
Short title: Pharmacotherapy for alcohol dependence 
 
Ee Teng Goh 
Medical Student 
 
Marsha Y Morgan 
Principal Research Associate and Honorary Consultant Physician 
UCL Institute for Liver & Digestive Health, 
Division of Medicine, Royal Free Campus, 
University College London, 
London NW3 2PF 
 
Author & Address for Correspondence: 
Dr M Y Morgan 
UCL Institute for Liver & Digestive Health, 
Division of Medicine, Royal Free Campus, 
University College London, 
Rowland Hill Street, 
Hampstead, 
London NW3 2PF 
Telephone +44 (0) 207 433 2873 
E-mail: marsha.morgan@ucl.c.uk 
 
KEYWORDS: acamprosate; alcohol dependence; baclofen; disulfiram; metadoxine; naltrexone; 
topiramate; pharmacogenetics; pharmacotherapy 
 
Word Count: 7,700 
2 
Summary 
 
Background 
The development of alcohol dependence is associated with significant morbidity and mortality.  For 
the majority of affected people the most appropriate goal, in terms of drinking behaviour, is 
abstinence from alcohol.  Psychosocial intervention is the mainstay of the treatment but adjuvant 
pharmacotherapy is also available and its use recommended.   
Aim 
This review aims to provide an updated analysis of current and potential pharmacotherapeutic 
options for the management of alcohol dependence.  In addition, factors predictive of therapeutic 
outcome, including compliance and pharmacogenetics, and the current barriers to treatment, 
including doctors’ unwillingness to prescribe these agents, will be explored.  
Methods 
Relevant papers were selected for review following extensive, language- and date-unrestricted, 
electronic and manual searches of the literature.  
Results 
Acamprosate and naltrexone have a substantial evidence base for overall efficacy, safety, and cost-
effectiveness while the risks associated with the use of disulfiram are well-known and can be 
minimized with appropriate patient selection and supervision.  Acamprosate can be used safely in 
patients with liver disease and in those with co-morbid mental health issues and co-occurring drug–
related problems.  A number of other agents are being investigated for potential use for this 
indication including, baclofen, topiramate and metadoxine.   
Conclusion 
Pharmacotherapy for alcohol dependence has been shown to be moderately efficacious with few 
safety concerns but it is substantially underutilized.  Concerted efforts must be made to remove the 
barriers to treatment in order to optimize the management of people with this condition. 
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BACKGROUND 
Alcohol Misuse, Health and Societal Costs  
Approximately 80% of the adult population in the United Kingdom (UK) consume alcohol.1  The 
majority of people drink responsibly with no associated harmful effects.  However, in England in 
2014, 22% of men and 16% of women, amounting to some 10.3 million adults, consumed alcohol 
in a way that was potentially or actually harmful to their health and well-being.1  It has been 
estimated that 5.9 % of the adult population in England (8.7% of men and 3.3% of women) are 
alcohol dependent.2  Based on current population estimates this equates to some 3.2 million people, 
although the figure more frequently quoted is 1.6 million.3   
In 2014/5 there were an estimated 1.1 million alcohol-related hospital admission in England, 
representing a 115% increase over 2003/4.4,5  A total of 8,697 wholly attributable alcohol-related  
deaths were registered in the UK during 2014, two-thirds of which were attributed to alcohol-related 
liver disease.6  However, a considerably higher estimate of 25,332 can be extrapolated from data 
provided by Public Health England based on a combination of all deaths relating to alcohol-specific 
conditions together with those where alcohol was causally implicated in some but not all cases.7  The 
estimated cost of alcohol misuse to the National Health Service (NHS) is £3.5 billion per annum, 
while the overall costs of alcohol-related societal harm approximates to £21 billion per annum.8   
In the United States of America (USA) the proportion of adults consuming alcohol is lower than in 
the UK at 46.3%.9  The 12-month prevalence of alcohol dependence is estimated to be 3.8 % (men 
5.4%; women 2.3%) while the estimated lifetime prevalence is 12.5% (men 17.4%; women 8.0%).10 
Alcohol dependence is associated with more than 85,000 deaths per year making it the third leading 
cause of preventable deaths in the USA;11 the estimated annual cost to society is more than $220 
billion.12 
Alcohol Dependence: Definitions, Diagnosis and Natural History 
A proportion of people consuming alcohol at harmful levels will develop alcohol dependence.  This 
condition is characterized by craving; tolerance; a preoccupation with alcohol; continued drinking 
in spite of harmful consequences; and the development of a physiological withdrawal syndrome 
when alcohol is suddenly stopped or consumption reduced.13  More exact definitions of this 
condition, which is officially recognized as a mental health disorder, are provided by the World 
Health Organization in the International Classification of Diseases (ICD)14 and by the American 
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Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders (DSM).15  
The ICD-10 and DSM-IV diagnostic criteria for alcohol dependence largely overlap and have high 
diagnostic concordance (Table 1).16   
The diagnosis of alcohol dependence is usually made by reviewing the clinical history but this can 
be imprecise if the patient is unaware, or reluctant to reveal the extent of their problems with 
alcohol.  However, questionnaires can facilitate the process.  The Alcohol Use Disorders 
Identification Test (AUDIT),17 for example, which was developed as a World Health Organization 
(WHO) collaborative initiative, is designed to identify people who have an alcohol use disorder; a 
score of  8 indicates hazardous/harmful drinking whilst a score of >16 indicates alcohol 
dependence.17 
Harmful alcohol use and alcohol dependence are relatively uncommon before the age of 15 but, 
thereafter, the prevalence increases steeply reaching a peak in the early twenties before declining.  
In one UK study the prevalence of alcohol dependence was 6% in 16 to 19 year olds, 8.2% in 20 to 
24 year olds, 3.6% in 30 to 34 year olds, and 2.3% in 50 to 54 year olds.18  Thus, substantial 
remission from alcohol dependence can occur, over time, often without intervention.19  However, 
those who remain dependent in their forties tend to have a more chronic course; most studies find 
that 70 to 80% of people entering specialist treatment will relapse in the year after completing 
treatment, most likely in the first three months.20, 21  Those who remain abstinent from alcohol for 
the first year after treatment have a relatively low risk of relapse thereafter.22 
The long term prognosis for people entering specialist treatment is comparatively poor.  Over a 10-
year period about one third have continuing alcohol problems; a third show some improvement and 
a third have a good outcome defined as either abstinence or moderate drinking.23  The mortality rate 
in this population is nearly four times the age-adjusted rate for people who are not alcohol 
dependent.  Much of the excess mortality is accounted for by disorders associated with co-morbid 
tobacco use, including, cardiovascular disease and aerodigestive malignancies.23,24 
The Treatment of Alcohol Dependence  
The severity of alcohol dependence can be assessed using the Severity of Alcohol Dependence 
Questionnaire (SADQ);25 the information provided can facilitates clinical management.   
The initial step in the treatment of alcohol dependence is withdrawal from alcohol.  In some, but not 
all instances, medical assistance will be required to prevent or to treat the withdrawal symptoms; 
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benzodiazepines are the drugs most commonly employed to facilitate this process. 13,26,27  Expert 
guidance on the withdrawal process, including all aspects of patient safety and general well-being, 
is available from the UK National Institute for Health and Care Excellence (NICE).13,26  People 
with mild dependence (SADQ score <15) do not usually need medically-assisted withdrawal; 
people with moderate dependence (SADQ 15 to 30) usually do need medical assistance, typically in 
a community setting;21 while people who are severely alcohol dependent (SADQ score >30) will 
require medically-assisted withdrawal, typically in an inpatient or residential setting.   
Withdrawal management is not a stand-alone process but should be the first phase of a longer term 
treatment plan.  For the majority of people who are dependent on alcohol the most appropriate goal, 
in terms of alcohol consumption, is total abstinence.  For people with significant psychiatric or 
physical co-morbidity, for example, a depressive disorder or alcohol-related cirrhosis, abstinence 
should always be the goal.  Nevertheless, some people will not accede to this advice, preferring a 
goal of moderation.  However, the more severe the level of dependence the less likely it is that a 
return to moderate or controlled drinking will be possible.22,28  Thus, where a clinician believes that 
abstinence is the most appropriate goal they should strongly advise this course, but should not deny 
treatment if this advice is not heeded.21   
Psychosocial intervention is the mainstay of the treatment for alcohol dependence.13  In the UK.  
NICE has provided detailed guidance on the provision of psychosocial support tailored to reflect the 
severity of the dependence.13  Services are delivered by both statutory and non-statutory providers  
and additional sources of support, such as self-help based interventions, are encouraged.  NICE also 
recommends the use of adjuvant pharmacotherapy for people with moderate to severe dependence 
once they had been successfully withdrawn from alcohol.13  They also recommend adjuvant 
pharmacotherapy for people with mild dependence who have either not responded to initial attempts 
to attain abstinence or have specifically requested it.13 
Similar approaches to the treatment of alcohol dependence are employed in Europe,29 the USA, 30-32 
and Australia.33  The latest French good practice recommendations,29 published by the Société 
Française d'Alcoologie in partnership with the European Federation of Addiction Societies, 
recommend the use of pharmacological treatments, combined with psychosocial support, for relapse 
prevention in patients with alcohol dependence.29  Likewise, in the USA, the Veterans 
Administration (VA),30 National Institute on Alcohol Abuse and Alcoholism (NIAAA),31 and 
Substance Abuse and Mental Health Services Administration (SAMHSA),32 all advocate the use of 
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adjuvant pharmacotherapy, in combination with behavioural intervention or addiction-focused 
counselling, for the management of alcohol dependence.  Finally, the Australian guidelines for the 
treatment of alcohol problems33 stipulate that pharmacotherapy should be considered for all 
alcohol-dependent patients following detoxification---best used in association with psychosocial 
supports as part of an after-care treatment plan. 
In this review the efficacy and safety of current and future potential pharmacotheraputic agents for 
the management of alcohol dependence will be assessed; their use in clinical practice will be 
detailed; factors predictive of treatment outcomes, including compliance and pharmacogenetics, 
will be delineated; and the current barriers to treatment will be explored. 
METHODS 
A general literature search was undertaken for articles on the generic topic ‘treatment of alcohol 
dependence’.  In addition a specific language-unrestricted electronic search was undertaken of the 
Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Library, MEDLINE, 
EMBASE, and Science Citation Index for pharmacotherapeutic trials published between 1966 to 
October 2016; this was supplemented by manual searches of the bibliographies of relevant papers, 
specialist journals, conference proceedings, and trial registries.  
RESULTS 
Licensed Pharmacotherapies for the Maintenance of Abstinence 
Disulfiram, acamprosate and naltrexone are the only pharmaceutical agents licensed for the 
maintenance of abstinence/relapse prevention in dependent drinkers in the majority of countries 
advocating the use of pharmacotherapy for the management of alcohol dependence (Table 2).  
Nalmefene has recently been licensed, in some countries, for use in people who are drinking at high 
risk levels who wish to reduce their alcohol consumption but not necessarily abstain. 
(i) Disulfiram  
Disulfiram has been used in clinical practice for the last 60 years; the oral preparation is licensed for 
relapse prevention in the UK, much of Europe, North America, Australia and parts of Asia.  Despite 
its apparent efficacy, when used in compliant and/or supervised patients, overall its use remains 
controversial. 
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Mode of action 
Alcohol is metabolized in the liver, via the enzyme alcohol dehydrogenase, to acetaldehyde and 
then to acetate via the enzyme acetaldehyde dehydrogenase (ALDH).  Disulfiram is an oral ALDH 
inhibitor.  The high levels of acetaldehyde which accumulate following alcohol ingestion in people 
taking disulfiram result in the development of a constellation of symptoms such as flushing, nausea, 
vomiting, tachycardia, hypotension, dyspnoea, dizziness and headache.34  These symptoms appear 
approximately 5 to 15 min after alcohol consumption and last from 30 minutes to several hours.  
The intensity of the reaction varies with the amount of alcohol consumed and can prove fatal.35,36  
The fear of the unpleasant effects provoked by alcohol is believed to be the primary mechanism 
facilitating  abstinence from alcohol.37,38 
Disulfiram has been used in the treatment of cocaine addiction particularly in people with co-
morbid alcohol–related problems.39-41  It inhibits the enzyme dopamine β-hydroxylase, which 
converts dopamine to norepinephrine, and may reduce cocaine use because it inhibits the associated 
noradrenergic-mediated ‘high’.42  
Efficacy 
There is no consensus on the optimal trial methodology for assessing the efficacy of disulfiram as a 
treatment for alcohol dependence.  It has long been held that it can not be appraised fairly in 
double-blind randomized controlled trials (RCTs) because the psychological fear of provoking an 
unpleasant disulfiram-alcohol reaction is key to its effectiveness.   
A number of systematic reviews and meta-analyses of the available trial data have been 
undertaken,13,41,43,44 with a degree of consensus on treatment efficacy.  The most comprehensive of 
these41 included a total of 22 RCTs, published between 1973 and 2010, comparing the efficacy of 
disulfiram to no treatment, placebo or other pharmacological treatments, irrespective of blinding or 
supervision of medication.  Based on the results of the open-label studies, where compliance was 
assured by supervision, disulfiram is a safe and efficacious treatment compared to no treatment or 
to other pharmacological agents.41  However, no evidence of efficacy was found in blinded RCTs or 
where there was no supervision.41   
Safety 
The side-effects associated with use of disulfiram include: headaches, drowsiness, lethargy, 
peripheral neuropathy, optic neuritis, hepatotoxicity and psychosis.36,45,46  In general the moderately 
severe side-effect profile can be offset by careful patient selection and supervision.   
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Therapeutic use 
There are a number of contra-indications to the use of disulfiram including: cardiovascular disease, 
systemic hypertension, severe personality disorder, suicidal risk/psychosis, pregnancy/breast-
feeding.  Caution is also advised in the presence of renal failure, hepatic or respiratory disease, 
diabetes mellitus and epilepsy.  NICE guidance suggests that disulfiram should be used as second-
line treatment after acamprosate or naltrexone or if a strong preference for its use is expressed.13  
Treatment should be started at least 24 hours after the last alcoholic drink in a dose of 200 mg per 
day; warnings should be provided about the nature and seriousness of the interaction with ingested 
alcohol and the presence of alcohol in foodstuffs, perfumes and aerosol sprays.  Supervision should 
be sought whenever possible.  Treatment, if successful and relatively free from side-effects, may be 
continued long-term. 
(ii) Acamprosate 
Acamprosate was introduced into clinical practice 30 years ago; the oral preparation is licensed for 
the maintenance of abstinence in alcohol dependent people in a wide range of countries including 
the UK, most of Europe, North America, Australia, parts of Asia and Africa and, most recently, 
Japan.   
Mode of action 
Acamprosate is the calcium salt of N-acetyl-homotaurine.  Its mechanism of action is unclear 
although it has been ascribed to aspects of glutamatergic and/or GABA-ergic neurotransmission; it 
is most frequently referred to as a ‘functional glutamate antagonist’.47  Recently, however, it has 
been suggested that acamprosate has no direct neurotransmitter target and that the therapeutic 
effects associated with its use are due to the co-administered calcium moiety.48,49  These findings 
have yet to be substantiated but the role of plasma and/or brain levels of calcium as a correlate or 
mediating factor in relation to the drug’s efficacy may need to be further explored.49 
Efficacy 
The results of a large number of RCTs and meta-analyses13,44,50-53 have shown that treatment with 
acamprosate, in conjunction with psychosocial support, significantly increases the proportion of 
alcohol dependent patients who remained completely abstinent from alcohol at 6 months.  Mann et 
al.,50 in a meta-analysis of 17 RCTs, involving 4087 participants, showed that 36.1% of patients 
receiving acamprosate achieved this endpoint compared with 23.4% of those receiving placebo; 
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overall the number needed to treat (NNT) to achieve continuous abstinence was 7.8 at 6 months and 
7.5 at 12 months.50   
A Cochrane review, including 24 RCTs with 6915 participants,51 showed a significant beneficial 
effect of acamprosate on a number of outcome measures other than abstinence; thus its use was 
associated with a reduction in the return to any drinking with a NNT of 9; a reduction in the risk of 
any drinking to 86% of the placebo rate and an increase in the number of abstinent days by 
approximately three per month.51  
Safety 
Acamprosate is not metabolized in the liver and has no impact on drugs subject to hepatic 
metabolism or those which affect the cytochrome P450 system.  Thus, it does not interact with 
alcohol and it is generally safe in patients with impaired hepatic function.  However, as it is 
excreted predominantly via the kidney it should be used with care in people with renal insufficiency.  
Acamprosate is well tolerated.46  Pharmacovigilance data in 1.5 million patients indicate no serious 
adverse events;54 the most commonly reported side-effect is diarrhoea.50  It does not have addictive 
potential and appears safe in overdose.47 
Therapeutic use 
Acamprosate is contraindicated in patients with severe renal impairment (creatinine clearance <30 
ml/min) and in those who are hypersensitive to the drug or any of its components. 
Guidelines in the UK, 13 France, 29 the USA, 30,31 and Australia33 recommend that acamprosate is 
used as first-line treatment for alcohol dependence.  It should be started as soon as possible after 
assisted withdrawal from alcohol in a daily divided dose of 1998 mg in people weighing >60 kg and 
of 1332 mg in those weighing <60 kg.13  There is no need to adjust the dose in people with mild to 
moderate hepatic impairment, although dose adjustment is recommended in people with moderate 
renal impairment.13  Treatment should continue for 6 months or longer in those deriving benefit 
who wish to continue; it can be continued if patients lapse but should be stopped if drinking persists 
beyond 4 to 6 weeks.13 
(iii) Naltrexone 
Naltrexone has been used in the management of opioid dependence since 1984; it was first used to 
treat alcohol dependence in 1994.  The oral preparation is licensed for relapse prevention in alcohol 
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dependent people in a wide range of countries including the UK, much of Europe, the USA, 
Australia and Asia.   
Mode of action 
Naltrexone and its active metabolite 6β-naltrexol act as opioid receptor antagonists, particularly at 
the μ-opioid receptor.  Its excretion is primarily renal.  The mechanism of its beneficial effect in the 
treatment of alcohol dependence is not fully understood although it is believed to reduce the reward 
effects of alcohol by modulating the dopaminergic mesolimbic pathway.55,56 
Efficacy 
A substantial number of RCTs have been undertaken to examine the efficacy of naltrexone for the 
treatment of alcohol dependence.   These have been the subject of a number of systematic reviews 
and meta-analyses employing varying inclusion criteria and drinking outcomes but, nevertheless, 
with broadly comparable results.13,44,52,54,57-59  Thus, in alcohol dependent people who have been 
withdrawn from alcohol, naltrexone, in combination with psychosocial support, has a modest, albeit 
significant beneficial effect on relapse rates, and in reducing alcohol intake. 
A Cochrane systematic review and meta-analysis, including 40 placebo-controlled RCTs of 
naltrexone, involving approximately 4500 participants, showed that treatment with naltrexone 
significantly reduced the risk of a return to heavy drinking to 83% of the placebo rate with a NNT 
of 9.58  Treatment was also associated with a 4% reduction in the number of drinking days; a 3% 
reduction in the number of heavy drinking days; and a reduction in the amount of alcohol 
consumed, on drinking days, by about 11 grams.  It did not, however, have a significant effect on 
the return to any drinking.58   The effect on overall abstinence rates was not determined. 
The results of a number of other meta-analyses confirm the effects of naltrexone in reducing the 
risk of a relapse to heavy drinking and the number of drinks consumed on drinking days; 57-59 some 
found that its use was, in addition, associated with a significant, albeit modest effect on the return to 
any drinking and overall abstinence rates.57,59 
Safety 
Naltrexone is metabolized in the liver via the enzyme dihydrodiol dehydrogenase predominantly to 
6β-naltrexol; the metabolites are further conjugation with glucuronide.  As naltrexone is not 
metabolized via the cytochrome P450 system interactions with drugs subject to hepatic metabolism 
are likely to be minimal.  However, increased plasma naltrexone concentrations have been reported 
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in patients with cirrhosis.  Naltrexone does not interact with alcohol and does not have addictive 
potential 
The most commonly reported side-effects are nausea, vomiting, dizziness, abdominal pain, reduced 
appetite, headache and day-time sleepiness; these are dose-dependent and appear to be worse in 
women.46  Hepatotoxicity has been reported in association with use of naltrexone in doses of >300 
mg/day to treat obesity.60  However, reviews of the available safety data have confirmed that 
hepatic toxicity is very unlikely to occur with the standard daily dose of 50 mg.13 
The most important safety consideration in relation to naltrexone is its reaction with opioid drugs.  
Opioid receptor blockade persists for 48 to 72 hours after the last oral dose; thus, in an emergency 
non-opioid analgesia would have to be used for pain relief.  If future use of opioids is anticipated, 
for example for elective surgery, then naltrexone should be discontinued ahead of time.   
Therapeutic use 
Naltrexone is contraindicated in individuals taking or likely to take opioids.  It is also 
contraindicated in people with acute hepatitis and acute or chronic liver failure.  It should be used 
with caution in people with serum transaminase activities exceeding three times the upper reference 
range and in patients with renal failure.  At present there is no consistent advice about monitoring of 
liver function tests in people receiving this drug but NICE guidance recommends that this should be 
considered in the elderly and the obese and that the drug should be discontinued immediately if the 
user feels unwell.13 
Guidelines in the UK, 13 France, 29 the USA, 30,31 and Australia 33 recommend that naltrexone should 
be considered as a first-line treatment for alcohol dependence.  Opioids should be stopped 7 to 10 
days beforehand but treatment can be started while patients are still drinking and during medically-
assisted withdrawal from alcohol.  An initial dose of 25 mg/day is recommended increasing over a 
period of two weeks to a maintenance dose of 50 mg/day.13  Treatment should be continued for 6 
months or longer in those deriving benefit who wish to continue; it can be continued if patients 
lapse but should be stopped if drinking persists beyond 4 to 6 weeks.13 
Combined treatment with acamprosate and naltrexone 
The effect sizes of acamprosate and naltrexone are modest and hence the effects of combining the 
two treatments has been explored.61,62   
12 
Keifer et al.,61 randomized 160 severely dependent drinkers to acamprosate, naltrexone, 
acamprosate/naltrexone combined or placebo for 12 weeks; all participants received specific relapse 
prevention intervention.  Both acamprosate and naltrexone and their combination had a positive 
treatment effect relative to placebo; the naltrexone/acamprosate combination was more effective 
than acamprosate alone but comparable in effect to naltrexone alone.  Anton et al.,62 randomized 
1383 much less severely dependent drinkers to the same four arms of treatment for 16 weeks; 
participants were further randomized to receive one of two different types of behavioural therapy.  
Outcomes improved in all participant groups but were significantly better in those receiving 
naltrexone together with intensive behavioural therapy; combining treatments had no additional 
beneficial effect.  Meta-analysis of these two trials confirmed that there were no significant 
differences in outcome favouring combined treatment.13,58 
Co-administration of acamprosate and naltrexone results in a 33% increase in the peak plasma 
concentrations of acamprosate and a reduction in the time to reach peak plasma levels but has no 
effect on the pharmacokinetics of naltrexone.  Thus, the incidence of diarrhoea and nausea was, as 
expected, significantly higher in the combined treatment groups, in both trials.58,61,62 
(iv) Nalmefene 
Nalmefene is an opioid system modulator which is structurally similar to naltrexone but it has a 
slightly different receptor profile.  It was first introduced into clinical practice for the treatment of 
alcohol dependence in the early 1990s.63-65  However, a meta-analysis of the three RCTs available 
from that time, which utilized daily doses in the 20 to 80 mg range, showed that although nalmefene 
had some beneficial effect on drinking outcomes none of these was significant.58   
Subsequently the drug was remarketed and licensed, on the basis of a small number of additional 
industry-sponsored initiatives, 66-70 for use in people who were drinking harmfully and wanted to 
reduce, though not necessarily stop, their alcohol consumption.  However, this so called ‘harm 
reduction’ approach to alcohol problems remain controversial.71  Thus, although several studies 
have demonstrated that controlled drinking is possible and that moderation-based treatments may be 
preferred over abstinence-only approaches, the evidence base for using this approach is not strong.   
Nevertheless, in 2013 nalmefene was approved by the European Medicines Agency as a treatment 
for alcohol dependence in people who wish to reduce their alcohol consumption but not necessarily 
abstain.  It was granted a licence in Scotland in October 2013.  In November 2014, NICE, 72 despite 
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concerns raised by its own Evidence Review Group, 73 recommended nalmefene, taken in a dose of 
18 mg daily, as needed, together with psychosocial support, as a treatment option for people 
drinking at high risk levels who, although alcohol dependent, did not need medically-assisted 
withdrawal from alcohol and wished to reduce rather than stop alcohol.  In France nalmefene is 
recommended as the first-line medication for reducing alcohol consumption in people who are 
alcohol dependent.29  Regulators and advisory bodies in other European countries for example, 
Germany and Sweden, have not recommended nalmefene for this indication.  The drug is not 
licensed for use in the USA or Australia 
Palpaceur et al.,74 have recently undertaken a meta-analysis of the efficacy and safety of nalmefene 
for the treatment of alcohol dependence.  They included all available RCTs of nalmefene 
irrespective of publication status, primary outcomes and licensed indications.63-70  Overall there was 
some evidence of a beneficial effect of nalmefene on the number of heavy drinking days per month 
and on total alcohol consumption but there were more withdrawals for safety reasons in the 
nalmefene–treated groups and the findings were not robust.  There was no evidence of a beneficial 
effect of nalmefene on the health outcomes examined.  The authors concluded that, at best, 
nalmefene has limited efficacy in reducing alcohol consumption but they were clearly aware of the 
limitations of their review and made specific recommendations for future studies.  
The licensing and subsequent recommendations for the therapeutic use of nalmefene have been 
widely criticized. 75,76  The major objections raised include: (i) the target population was defined 
following an unplanned subgroup analysis of the available trials, thus departing from the intention-
to-treat principle; (ii) the placebo comparator was inappropriate – the efficacy of nalmefene should 
have been compared with naltrexone which is used off- label for this indication; (iii) the supposed 
advantage conferred by nalmefene on alcohol consumption levels was of questionable clinical 
relevance; and, (iv) no evidence of wider harm reduction was sought or provided in the trials 
included for review. 
As nalmefene is an opioid receptor antagonist the same precautions and guidance provided for 
naltrexone in relation to opioid usage should apply.  The most commonly encountered side-effects 
are nausea, insomnia, dizziness, vomiting and fatigue.  However, use of naltrexone has not been 
associated with evident hepatotoxicity.  Naltrexone is considerably more expensive than the other 
drugs licensed to treat alcohol dependence, at least in the UK.   
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Emerging Treatments for Alcohol Dependence 
A number of other agents have been proposed and are currently under investigation as potential 
treatment options for alcohol dependence.77-82  The majority already have a therapeutic profile and 
are being repurposed for use in this field.  Of these baclofen, topiramate and metadoxine are the 
best known, but others with an evidence base include: (i) gabapentin: an inhibitor of presynaptic, 
voltage-gated sodium and calcium channels which is approved for the treatment of epilepsy and 
neuropathic pain; (ii) ondansetron: a serotonin 5-HT3 receptor antagonist which is used to prevent 
nausea and vomiting in selected clinical situations; (iii) varenicline: a nicotinic receptor partial 
agonist which is used for smoking cessation; and, (iv) aripiprazole: an antipsychotic which is a 
partial dopamine agonist.  None of these compounds is licenced for the treatment of alcohol 
dependence but can of course be used off-label. 
(i) Baclofen 
Baclofen is a selective γ-aminobutyric acid (GABA)-B receptor agonist which was originally 
approved for the treatment of spasticity associated with multiple sclerosis and spinal cord lesions.  
Activation of GABA-B receptors might reduce anxiety and it was for this reason that it was 
identified as a potential treatment for alcohol withdrawal and dependence.   
A number of placebo-controlled RCTs of baclofen, 30 to 60 mg/day, have been undertaken but with 
widely different results. 83-88  A series of trials undertaken by one Italian group,83-85 including a trial 
in patients with cirrhosis,84 showed significantly higher abstinence rates in participants receiving 
baclofen compared with placebo, together with improvements in other drinking outcomes.83,85  
However, studies undertaken in the United States,86 Australia,87 and Israel88 showed no beneficial 
effects of baclofen over placebo on any drinking outcome, although a post hoc analysis of the 
Australian data showed that baclofen conferred some benefit, in terms of relapse behaviour, in a 
subgroup of patients with a co-morbid anxiety disorder.87  Overall the drug was well-tolerated. 
The divergent results of these studies have not been fully explained.  One suggestion is that they 
may relate to the relatively low doses of baclofen used in the trials undertaken to date.  Baclofen is 
rapidly absorbed and excreted primarily unchanged by the kidney but there is significant inter-
subject variation in its pharmacokinetics, which could potentially be reflected in differences in 
population responses.  This view was supported by the self-reported experience of a French 
physician who treated his own alcohol dependence and anxiety disorder with baclofen in a dose of 
270 mg/day.89,90  The consequent media interest resulted in an unprecedented demand, in France, 
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for off-label treatment with high dose baclofen.91,92  In 2014, baclofen, in doses up to 300 mg/day, 
was authorized by the French Health Agency (FHA) as a second-line drug to prevent relapse or 
reduce drinking in people with alcohol dependence 93  This authorization which is a specific 
measure known as a  ‘temporary recommendation for use’ (TRU) requires centralized collection of 
follow-up data.93  
Studies utilizing high doses of baclofen are now being reported.  A German group randomized 56 
alcohol dependent people to either baclofen titrated to 270 mg/day or placebo.94  The mean daily 
dose of baclofen achieved during the 12 week high dose phase of the trial was 180 mg and during 
this phase abstinence rates were higher in those receiving baclofen than placebo (68.2% vs. 23.8%, 
p = 0.014); baclofen also had a significant beneficial effect on overall abstinence rates during the 20 
week trial (42.9% vs. 14.3% p=0.04).  However, there was no relationship between the 
individualized doses of baclofen and drinking behaviour outcomes suggesting that the efficacy of 
baclofen does not have a clear dose threshold.  . 
A multicentre RCT 95 undertaken in the Netherlands randomly assigned 151 alcohol dependent 
individuals to six weeks titration and ten weeks maintenance with either low-dose baclofen (30 
mg/day), high-dose baclofen (up to 150 mg/day; mean 94 mg/day), or placebo.  No significant 
differences were observed between the groups in the time to first relapse; the proportions who 
relapsed; the proportions who attained continuously abstinence; the cumulative abstinence duration; 
or the drop-out rates.  Two important considerations need to be taken into account in relation to this 
trial viz: (i) the drug dosage schedule and degree of psychosocial support differed between patients 
recruited from inpatient and outpatient facilities; and, (ii) the continuous abstinent rates were very 
high viz. high dose baclofen 62.5% cf. placebo 65.9%. 
The results of two French high-dose baclofen studies, which will be pivotal in determining whether 
the TUR currently in place will be removed by the FHA or made official, have been reported but in 
abstract form only.96,97  In the  first of these – the ALPADIR study96 - 320 alcohol dependent 
outpatients attending French specialist alcohol treatment clinics were randomized to baclofen 
(target dose 180 mg/day attained by 66%) or placebo using a 7-week titration, and 17 weeks 
maintenance paradigm.  The proportions of patients who were continuously abstinent throughout 
the trial were similar in both groups viz. baclofen 11.9%; placebo 10.5%.  Post-hoc subgroup 
analyses showed more evidence of benefit in the heaviest drinkers and when the outcome variable 
selected was the overall reduction in consumption.   
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The second of these French studies--the multicenter BACLOVILLE study—was designed to 
explore pragmatic risk reduction in a general practice.98  A total of 320 attendees diagnosed as 
having an alcohol use disorder were randomized to treatment with baclofen, individually titrated to 
a maximum dose of 300 mg/day, or placebo for 12 months.  There was no requirement for 
participants to be withdrawn from alcohol or to receive psychosocial support.  The primary outcome, 
which was the proportion of patients who achieved WHO defined safe drinking levels (1-20 g/day 
for women and 1 - 40 g/day for men) was attained by 56.8% of the baclofen group and 36.5% of the 
placebo group (risk reduction 1.56 [95% CI 1.15, 2.11]; p = 0.004).  At present no other 
information on outcome variables or safety is available. 98 
These four high dose baclofen studies are not directly comparable as they differ considerably in 
aspects of patient selection; study design and duration; dosage schedules and outcome variables.  In 
addition the reporting of the two French studies is still incomplete.  Thus overall conclusions about 
the efficacy of baclofen as a treatment for alcohol dependence can not be made at this time. 
Baclofen and alcohol are both central nervous depressants so there are considerable safety concerns 
around use of this drug.46  Fatigue, sleep disorders and vertigo/dizziness were more frequent in 
those taking the active drug particularly in the high-dose studies.  Reports of further adverse event 
such as major sedation, 99 seizures, 100 mania, 101 and sleep apnoea102 are increasing in parallel with 
increased use of this drug.   
(ii) Topiramate 
Topiramate is a potent antiepileptic with strong neuroprotective properties.  It has many proposed 
targets of action, including facilitation of GABA-A receptor activity, and reduction of glutamate 
activity in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate receptors.  Like 
many other drugs proposed for the treatment of alcohol dependence it is thought to reduces 
mesolimbic dopaminergic activity.  A small number of RCTs of topiramate versus placebo, no 
treatment or an active comparator for the treatment of alcohol dependence have been undertaken 
and subjected to systematic review with or without meta-analysis.103,104  A systematic review of 
topiramate versus placebo 103 including seven RCTs, involving 1,125 participants, demonstrated 
significant, though moderate, benefits of topiramate for abstinence and heavy drinking outcomes.  
A more generic Cochrane review of anticonvulsants in the management of alcohol dependence 104 
included a separate analysis of six placebo-controlled RCTs of topiramate, involving 970 
participants, and showed a modest but significant beneficial effect on heavy drinking and the 
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number of drinks per drinking day but a rather less robust effect on the number of abstinent days.  
Topiramate in a dose of 300 mg/day appears to be relatively well tolerated with the most common 
adverse effects being dizziness, paraesthesia, and anorexia.  However, all the trials undertaken to 
date are short–term; with longer–term treatment there is potential, given the drug’s safety profile, 
for the emergence of other side effects such as difficulties with memory and cognitive impairment.   
(iii) Metadoxine 
Metadoxine (pyridoxal L-2-pyrrolidone-5-carboxylate) is an ion pair salt of pyridoxine and L-
pyroglutamate.  It is approved in several European countries, India, the Russian Federation, and 
Brazil for treating acute alcohol intoxication, based on its ability, when given as a single 900 mg 
intravenous dose, to facilitate the elimination of alcohol from blood and tissues.105  Metadoxine has 
also been used to treat alcohol dependence based on its properties as a selective serotonin receptor 
subtype 5-HT2B antagonist and a monoamine-independent GABA modulator.
106   In an open label 
study patients treated with metadoxine, 1500 mg/day in divided doses, were significantly more 
likely to maintain abstinence at 3 months than untreated controls (44.8% vs. 21.6%; p <0.004).107  
In a randomized, open-label study in patients with severe alcoholic hepatitis survivors who received 
metadoxine, in addition to standard therapy, were significantly more likely to maintain abstinence at 
6 months than those who did not (74.5% vs. 59.4%, p =0.02).108  Metadoxine has an excellent safety 
record.109  Its use needs to be further explored. 
Pharmacotherapy in Specific Situations 
Alcohol-related liver disease 
The most important management goal for patients with significant alcohol-related liver injury is 
abstinence from alcohol.  Nevertheless this aspect of their management, and in particular the use of 
adjuvant pharmacotherapy to achieve this goal, is inconsistently addressed in the literature with 
scant or no mention by some 110,111 but specific mention by others.112-114 
No RCTs of the three main medications currently licensed for the treatment of alcohol dependence 
have been undertaken in people with significant alcohol-related liver injury.  Of these acamprosate 
has the best safety profile.46,51,54  It is not metabolised in the liver and there are no reported 
instances of hepatotoxicity.  Further, Delgrange et al., 115 reported, in a single dose RCT, that 
acamprosate does not adversely affect neuropsychiatric status in patients with Child’s Grade A and 
B cirrhosis.  Hepatotoxicity has not emerged as a clinical problem with naltrexone in standard doses, 
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although hepatotoxicity is a concern, in certain circumstances, when higher doses are used.60  
Patients with advanced liver disease are particularly vulnerable to naltrexone-induced 
hepatotoxicity116 so its use in this situation would need to be montored carefully.  Use of disulfiram 
has been complicated by the development of hepatotoxicity which is associated with a mortality 
rate of 28%.117  It is best avoided in patients with chronic liver disease. 
Baclofen in a dose of 30 mg/day has been shown, in one RCT, to be a safe and effective treatment 
for alcohol dependence in patients with cirrhosis.84  However, the study population was very 
carefully selected to excluded people with diabetes, hepatic encephalopathy, psychiatric co-
morbidity and co-morbid drug misuse.  Hence, the safety findings in this study may not be 
generalizable.  In addition, much higher doses of baclofen are now being used to treat alcohol 
dependence but no information is available on the safety profile associated with these dose levels in 
patients with liver disease; until this information is available considerable caution should be 
exercised in use of this drug in this setting.  
Topiramate has only rarely been linked to clinically apparent liver injury.  However, as it is 
metabolized via CYP3A4 it may potentiate the hepatotoxicity associated with other drugs 
metabolised via this system.  The anti-epileptic drug sodium valproate, for example, inhibits the 
first enzyme in the urea cycle and its use may be associated with the development of 
hyperammonaemic encephalopathy; co-medication with topiramate increases the circulating levels 
of free valproate and significantly increases the risk of this potentially fatal complication.118   
Metadoxine has an excellent safety profile and has been shown to have utility not only to treat 
alcohol dependence but also alcohol-related liver disease.  It accelerates the normalization of liver 
function tests and the liver appearance on ultrasound in individuals with alcohol-related steatosis, 
even in those who do not completely abstinent from alcohol.119  In patients with severe alcoholic 
hepatitis treated with prednisolone the addition of metadoxine significantly improved survival, 
compared with prednisolone alone, both at 30 days (74.3% vs.45.7%; p = 0.02) and at 90 days 
(68.6% vs. 20.0%; p = 0.0001).120  The addition of metadoxine also significantly reduced the 
development/progression of hepatic encephalopathy (29.6% vs. 60.0%; p = 0.008) and hepatorenal 
syndrome (31.4% vs. 54.3%; p = 0.05).120  These beneficial effects likely relate to the fact that 
metadoxine is an antioxidant and has also been shown to inhibit hepatic lipid accumulation and 
protect against glutathione depletion.121  Further studies with this drug are clearly needed. 
19 
Both the American and European Associations for the Study of the Liver 122,123 recommend the use 
of acamprosate and naltrexone, in conjunction with psychosocial support, to decrease the likelihood 
of relapse in patients with alcohol-related liver disease.  Future recommendations with regard to the 
use of baclofen in this setting will require a more extensive evidence base 
Co-morbid psychiatric disorders and co-occurring drug misuse 
Psychiatric co-morbidity and co-occurring drug misuse are common in people with alcohol 
dependence.  However, pharmacological intervention for alcohol dependence, in these situations, 
has received very little attention.13  
People with alcohol dependence are frequently anxious and/or depressed but these symptoms often 
remit once they achieve abstinence or significantly reduce their alcohol intake.13  Medication for 
depression and anxiety is often ineffective in people who are consuming significant amounts of 
alcohol either for relieving the psychiatric symptoms or for curbing the alcohol misuse.124,125  In 
consequence, guidance from NICE recommends focusing on the management of the alcohol misuse 
as the first priority.13  Acamprosate can be used to facilitate abstinence under these circumstances; it 
is well-tolerated; it does not interact with alcohol or have addictive potential; and is safe in 
overdose.  Naltrexone and disulfiram both interact with alcohol and are less safe in these situations.  
If, however, symptoms of significant anxiety or depression remain after 3 to 4 weeks of abstinence 
from alcohol then patients should be referred appropriately for specific management of their mental 
health disorder.126  People with alcohol dependence and significant co-morbid mental problems, 
such as schizophrenia or bipolar disorder, and those assessed to be at high risk of suicide, should be 
referred to a psychiatrist to make sure that effective assessment, treatment and risk-management 
plans are put in place.127  
Alcohol and illicit drug dependence often co-occur.  Treatment of the drug misuse must be 
optimised using psychosocial and/or pharmacological approaches, as appropriate, 128 but the alcohol 
misuse must also be specifically addressed.  Naltrexone is not an option in individuals who have 
used or are using opioids and there are no published studies of acamprosate in opioid-dependent 
populations.  Nevertheless, acamprosate is safe, well-tolerated and does not interact with the 
commonly used illicit drugs or with methadone or the antiviral agents use to treat co-morbid 
hepatitis C or HIV infection. 
 
 
20 
Predictors of Outcome 
The drugs currently available for the treatment of alcohol dependence have only modest effects and 
attempts have been made to optimise treatment by identifying people more likely to respond.  These 
attempts are confounded by the so–called ‘placebo effect’ and by factors pertaining to adherence 
and compliance with treatment.   
The placebo effect 
The placebo effect can confound efforts to determine treatment effectiveness in clinical trials.  The 
greater the placebo group response the more difficult it is to demonstrate medication efficacy.  The 
placebo response in trials of drugs for alcohol dependence appears to be even greater than, for 
example, trials in depression and schizophrenia.  Further, more recent studies in alcohol dependence 
have shown greater placebo group improvement, an effect which persists even after controlling for 
several other moderators, including concomitant interventions.  Thus, attempts will need to be made 
to more effectively isolate alcohol medication effects in future studies.129, 130 
Compliance and adherence 
The clinical effectiveness of any medication is highly influenced by the degree of patient 
compliance and adherence to treatment regimens.  Trials of drugs for the treatment of alcohol 
dependence, as in the addiction field generally, are characterized by high dropout rates and 
generally low levels of compliance with treatment.42, 51, 58  However, very little information is 
available on the factors which affect compliance in this setting.  Rohsenow et al.,131 found that 
compliance with naltrexone was better in those who believed that the medication would help them 
maintain abstinence, and was not predicted by demographic or pre-treatment alcohol use, 
commitment to abstinence or perceptions about their own ability to abstain.  Supervision or 
witnessing, which are employed primarily in patients receiving disulfiram, are a major determinant 
of compliance and hence effectiveness.42   
Demography, drinking variables and co-morbidities 
A number of demographic variables, along with features of the drinking behaviour and potential co-
morbidities, have been explored and several possible predictors of outcome identified, but the 
results are inconsistent.  The most favourable results in people receiving unsupervised disulfiram 
were in those who were older; more socially stable; impulsive; and motivated.34,132  Pooled data 
from seven placebo-controlled RCTs of acamprosate, involving 1485 participants, showed that 
there were no significant relationships between treatment outcome and gender, the age of onset, the 
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severity of dependence or family history.133  A number of studies have reported that people with a 
family history of alcohol-related problems are more likely to benefit from naltrexone but other 
identified predictors such as high levels of craving, early age of onset, concomitant drug misuse and 
co-morbid depression are not as robust.134-136  Mann et al., 137 have shown, using functional cerebral 
MRI, that alcohol dependent people with high brain activity in the ventral striatum in response to 
alcohol cues had significantly better treatment outcomes with naltrexone.  High cue reactivity as an 
‘endophenotype’ might help to prospectively identify alcohol-dependent patients likely to respond 
to treatment.  However, for obvious reasons, this approach is likely to be limited to studying the 
mechanisms of treatment responses.  
Pharmacogenetics  
A number of studies have examined the role of the single nucleotide polymorphism (SNP) 
rs1799971 in the μ-opioid receptor 1 gene (OPRM1) in relation to the response to treatment with 
naltrexone.  Several, but not all, have reported a link between possession of the G allele of 
rs1799971 and better drinking outcomes.  Anton et al.,138 for example, showed that individuals 
carrying the G allele were more likely to attain abstinence and to have less heavy drinking days.  
However, Coller et al.,139 found no significant association between rs1799971 genotype and any 
treatment outcome.  Jonas et al.,140 recently undertook a meta-analysis of eight trials, involving 
1365 participants, which assessed rs1799971 genotype and the response to naltrexone and found no 
association between possession of the G allele and the return to any drinking or to the return to 
heavy drinking.  
Karpyak et al.,141 reported an association, in people treated with acamprosate, between abstinence 
length and polymorphisms in the glutamate receptor, ionotropic, N-methyl D-aspartate 2B (GRIN2B) 
gene, which encodes for the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor.  
Carriage of the minor alleles of two SNPs, rs2058878 and rs2300272, which are in strong linkage 
disequilibrium, was associated with longer abstinence duration. 
Kranzler et al.,142,143 explored the relationship between the outcomes of treatment with topiramate 
and polymorphisms in the glutamate ionotropic receptor kainate type subunit 1 (GRIK1) gene, 
which encodes the GluK1 subunit of the glutamatergic kainate receptor.  In alcohol dependent 
people who were homozygous for the C allele in rs2832407 treatment with topiramate resulted in a 
greater reduction in alcohol consumption than in carriers of the A allele.  It has been suggested that 
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homozygosity for the C allele moderates peoples’ desire to drink and increases their belief in their 
ability to abstain.142,143   
The serotonin transporter (5-HTT) is encoded by the gene, solute carrier family 6 member 4 
(SLC6A4).  The promotor region of SLC6A4 contains a polymorphism with short (S) and long (L) 
repeats in a 5’-HTT-linked polymorphic region (5’-HTTLPR).  Johnson et al.,144 showed that 
individuals homozygous for the L allele had better drinking outcomes following treatment with 
ondansetron than carriers of the S allele.  
No studies have been undertaken, to date, to assess the clinical utility of genotype-guided 
medication selection or dosing strategies, and in only one, which was unfortunately substantially 
underpowered, were participants randomized to treatment with naltrexone or placebo by 
genotype.145  Future studies may ultimately define a range of genetic variations that have clinical 
value in predicting response to the drugs used to treat alcohol dependence.  
Barriers to Treatment  
Between 1.6 to 3.2 million people in England are alcohol dependent.2,3  In 2014-15 only 150,640 
(4.7 to 9.4%) of those affected received specialist treatment for their alcohol problems and this was 
only successfully completed in an estimated 47,900.146  However, despite the fact that 
pharmacotherapy has been shown to be cost-effective this treatment approach is significantly 
underutilized.13  Thus, in 2015, only 196,000 items were prescribed in primary care and NHS 
hospital settings throughout England although separate data were not available for naltrexone as it 
is also prescribed for drug use disorders.  Overall acamprosate accounted for 71% of the prescribed 
items whilst nalmefene accounted for 2.2%.146  While overall there has been a steady increase in the 
number of items dispensed this remains small given the size of the population at risk (Figure 1).  
Recent data from Australia show that only 3% of people with alcohol dependence receive 
pharmacotherapy and, of those only 15 to 25% receive the minimum period of 3 months treatment 
recommended in the National Guidelines.147 
There are several possible barriers to the use of pharmacotherapy for the treatment of alcohol 
dependence (Table 3).  Thus, for example, doctors may be reluctant to prescribe because they lack 
knowledge of or familiarity with the products available,148 whilst certain statutory and non-statutory 
agencies may be reluctant to prescribe on philosophical grounds or simply because they are not able 
to (Table 3). 
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There are also other broader issues.  Thus, the development of pharmaceutical agents to treat 
alcohol use disorders is hampered by an incomplete understanding of the neurobiological 
background of alcohol dependence and inconsistent results from genome wide association studies 
which have, overall, failed to identify robust, replicable targets for drug development.  Further 
investigation and investment is clearly needed. 
CONCLUSION 
Individuals with alcohol use disorders often fail to receive care, particularly evidence-based care, 
and there is clear evidence that although drug treatment for alcohol dependence is safe and cost-
effective it is substantially underutilized.  Efforts must be made to overcome the current barriers to 
treatment which, in large part, reflect unwillingness by doctors to prescribe these medications. 
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Table 1. Comparisons between the ICD and DSM diagnostic criteria for alcohol dependence 
 
Criterion  
 
 
ICD-10* 
 
Criterion  
 
 
DSM-IV* 
1  
Strong desire or sense of 
compulsion to use the 
substance  
N/A  N/A  
2  
Impaired capacity to control 
use as evidenced by the 
substance often being taken in 
larger amounts or over a longer 
period than intended or by a 
persistent desire or 
unsuccessful efforts to control 
use  
3  
 
 
 
4 
Persistent desire or one or more 
unsuccessful efforts to cut down or 
control drinking  
Drinking in larger amounts or over a 
longer period than the person 
intended 
 
3  
 
Physiological withdrawal  2  Physiological withdrawal  
 
4  
 
Tolerance  1  Tolerance  
5  
Preoccupation with substance 
use as manifested by important 
interests being given up or 
reduced or a great deal of time 
spent in activities necessary to 
obtain, take, or recover from 
the effects of the substance  
5  
 
 
 
6 
Important social, occupational, or 
recreational activities given up or 
reduced because of drinking  
A great deal of time spent in 
activities necessary to obtain, to use 
or to recover from the effects of 
drinking 
6  
Persistent substance use 
despite clear evidence of 
harmful consequences  
7  
Continued drinking despite 
knowledge of having a persistent or 
recurrent physical or psychological 
problem that is likely to be caused 
or exacerbated by drinking  
 
*In both the ICD-10 and the DSM-IV criteria, a diagnosis of alcohol dependence is made if three or 
more of the criteria are present together at some time during the previous 12 months  
 
Abbreviations:  
ICD-10:   International Classification of Diseases, 10th Edition 14  
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 15  
N/A: Not Applicable 
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Table 2. Essential details of the three drugs most widely licensed for the treatment of alcohol dependence  
 
 
 
Drug Order Contraindications Precautions Side-effects Dosage Duration  Comments 
Disulfiram Second-line  Cardiovascular disease  
 Systemic hypertension 
 Severe personality disorder 
 Suicidal risk or psychosis  
 Pregnancy & breast-feeding.   
 
Caution in the presence of renal 
failure, hepatic or respiratory 
disease, diabetes mellitus and 
epilepsy 
Warnings: 
 
 Nature/seriousness 
of the interaction 
with ingested 
alcohol; 
 Alcohol in 
foodstuffs, 
perfumes, aerosol 
sprays 
 Headaches 
 Drowsiness  
 Lethargy  
 Peripheral neuropathy  
 Optic neuritis 
 Hepatotoxicity 
 Psychosis. 
200 mg/day Long-term 
if required 
Start 24 hr after 
last drink 
 
Treatment most 
effective if 
supervised or 
witnessed 
Acamprosate First-line Severe renal impairment 
(creatinine clearance <30 
ml/min) 
 
 
  Diarrhoea 
 Anorexia 
 Flatulence 
 Nausea 
 Pruritus 
 Dry mouth 
 Paraesthesia 
 Fatigue 
Weight: 
 
> 60 kg  
1998 mg/day  
 
< 60 kg  
1332 mg/day 
 
Reduce in 
moderate 
renal failure 
6 months, 
or longer 
Safe for use in 
mild to 
moderate 
hepatic failure 
Naltrexone First-line  Acute hepatitis  
 Acute liver failure 
 Chronic liver failure 
 Use of/likely use of opioids 
 
Caution: if serum transaminase 
activities exceeding three times 
the upper reference range and in 
patients with renal failure.   
Warning: 
 
Naltrexone blockade 
persists for 48-72 
hours after the last 
oral dose 
 Nausea  
 Vomiting  
 Dizziness 
 Abdominal pain  
 Anorexia 
 Headache  
 Day-time sleepiness 
 Hepatotoxicity with 
high doses 
Start with: 
25 mg/day  
 
Maintenance 
50 mg/day 
6 months, 
or longer 
Stop opioids 
7 to10 days 
before 
prescribing  
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Table 3. Barriers to the use of pharmacotherapy for alcohol dependence 
 
 
Barrier 
 
Patients 
 
Alcohol treatment services 
 
Doctors 
 
    
Information Lack/poor awareness 
 
Lack/poor awareness Lack/poor awareness 
  Lack/poor knowledge 
 
Lack/poor knowledge 
 
Medication 
 
Reluctant to take  
 
 
Lack of confidence in efficacy 
 
Lack of confidence in efficacy  
 Side-effects 
 
Side-effects Side-effects 
  Cost 
 
Cost 
    
Delivery  Unable to prescribe ‘in-house’ 
 
No specific guidance available 
  Unable to effectively monitor 
 
Need for psychosocial support 
 
   Lack of time 
 
   Unable to effectively monitor 
 
    
Resources Cost of prescription 
 
  
    
Philosophy Alternative addiction 
 
‘Medicalises’ the condition Ambivalence 
  Against tenets of AA 
 
 
 
Abbreviation: AA: Alcoholics Anonymous 
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Legend to Figure 
 
Fig. 1. Number of prescription items for the treatment of alcohol dependence prescribed  
in primary care in England 2004 to 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Adapted from the Prescribing Analysis and Cost Tool (PACT) from NHS Prescription 
Service of the NHS Business Services Authority Health and Social Care Information Centre 146 
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